PPARD: Peroxisome proliferator-activated receptor delta
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Ligand-activated transcription factor key mediator of energy metabolism in adipose tissues.
- Drugs that act on it: 8
- Approved: 2
- In phases 1 to 3: 6
- Sponsors: 5
Who Is On It, and How Far Along
Every drug ChEMBL records acting on PPARD, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Other
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Gilead Sciences113%
- GSK113%
- Ipsen113%
- Senju Pharmaceutical Co., Ltd.113%
- T3D Therapeutics, Inc.113%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule450%
- Other450%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Peroxisome proliferator-activated receptor delta agonist.| Elafibranor | Approved | Ipsen | Small molecule | Agonist | — | 9 | — |
| Seladelpar | Approved | Gilead Sciences | Small molecule | Agonist | — | 7 | — |
| Fonadelpar | Phase 3 | Senju Pharmaceutical Co., Ltd. | Small molecule | Agonist | — | 0 | — |
| DB959 | Phase 2 | T3D Therapeutics, Inc. | Other | Agonist | — | 0 | — |
| GW501516 | Phase 2 | GSK | Small molecule | Agonist | — | 0 | — |
| AVE0847 | Phase 1 | — | Other | Agonist | — | 0 | — |
| CER-002 | Phase 1 | — | Other | Agonist | — | 0 | — |
| KD3010 | Phase 1 | — | Other | Agonist | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Neurodegenerative disease
- 0.44
- Type 2 diabetes mellitus
- 0.40
- Familial hyperlipidemia
- 0.40
- Cardiovascular disorder
- 0.38
- Cholangitis
- 0.37
- Pruritus
- 0.35
- Esophageal disorder
- 0.31
- Abnormality of the skeletal system
- 0.28
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- PPARD
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3979, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q03181, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets